BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 236 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $18,062,680 | +2.7% | 2,551,226 | +2.2% | 0.48% | +15.8% |
Q2 2023 | $17,580,239 | -9.7% | 2,497,193 | +7.0% | 0.42% | -9.9% |
Q1 2023 | $19,466,269 | -10.3% | 2,334,085 | +23.4% | 0.46% | -11.1% |
Q4 2022 | $21,705,661 | +0.6% | 1,890,737 | +10.4% | 0.52% | -6.3% |
Q3 2022 | $21,578,000 | +39.6% | 1,712,507 | +17.2% | 0.56% | +23.8% |
Q2 2022 | $15,458,000 | +171.3% | 1,461,091 | +108.7% | 0.45% | +104.5% |
Q1 2019 | $5,698,000 | +0.9% | 700,000 | 0.0% | 0.22% | -17.6% |
Q4 2018 | $5,649,000 | +5.8% | 700,000 | 0.0% | 0.27% | +38.3% |
Q3 2018 | $5,341,000 | +272.7% | 700,000 | +180.0% | 0.19% | +250.9% |
Q2 2018 | $1,433,000 | -67.5% | 250,000 | -73.0% | 0.06% | -70.7% |
Q1 2018 | $4,412,000 | +10.6% | 925,000 | +13.8% | 0.19% | +3.9% |
Q4 2017 | $3,989,000 | +69.2% | 812,500 | +80.6% | 0.18% | +66.1% |
Q3 2017 | $2,358,000 | – | 450,000 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |